Reaction
Invasive Lobular Breast Carcinoma reporting signals
As of the last recalculation, Invasive Lobular Breast Carcinoma appears in 506 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is EXEMESTANE (PRR 83.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Exemestane | 40 | 83.3 | 83.5 |
| Goserelin | 23 | 73.8 | 73.9 |
| Letrozole Tablets | 62 | 60.3 | 60.4 |
| Fulvestrant | 41 | 55.5 | 55.5 |
| Letrozole | 69 | 53.2 | 53.3 |
| Ribociclib | 29 | 40.0 | 40.1 |
| Anastrozole Tablets | 20 | 39.9 | 39.9 |
| Everolimus Tablets | 14 | 35.3 | 35.3 |
| Bleomycin Sulfate | 8 | 32.4 | 32.4 |
| Anastrozole | 24 | 28.2 | 28.2 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 9 | 16.0 | 16.0 |
| Docetaxel Anhydrous | 23 | 14.7 | 14.7 |
| Docetaxel | 23 | 14.7 | 14.7 |
| Palbociclib | 30 | 13.7 | 13.7 |
| Medroxyprogesterone Acetate | 14 | 11.9 | 11.9 |
| Abemaciclib | 5 | 10.4 | 10.4 |